跳至主要内容
临床试验/NCT00314613
NCT00314613终止4 期

Functional Brain Imaging and Employment in First-Episode Psychotic Patients Treated With Risperdal

Duke University4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2006年4月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
30
试验地点
4

研究概览

简要总结

Assured treatment with Risperal CONSTA will provide first-episode patients, who have a greater potential for therapeutic response, with their best opportunity for continued improvement in cognitive function beyond three months of treatment.

详细描述

First episode patients have a greater potential for therapeutic response than multi-episode patients, and many of them also havea great desire to rejoin the workforce. Unfortunately, first episode patients become non-compliant or intermittently compliant with prescribed antipsychotic treatment at least as frequently as multi-episode patients. We believe that assured treatment with Risperal CONTSTA will provide first episode patients wiwth their best opporutnity for continued improvement in cognitive function beyond 3 months of treatment and that improvements in cognitive function will be associated with a greater likelihood of employment, real-world outcomes, such as independent living, as well as measures of brain function.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • male or female between 18-40 years of age
  • meet DSM-IV criteria for first-episode schizophreniform, schizophrenia or schizoaffective disorder

排除标准

  • pregnant & breast-feeding women
  • patients with known sensitivity to oral Risperdal

研究者

发起方
Duke University
申办方类型
Other

研究点 (4)

Loading locations...

相似试验